WO2012025155A1 - Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases - Google Patents

Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases Download PDF

Info

Publication number
WO2012025155A1
WO2012025155A1 PCT/EP2010/062520 EP2010062520W WO2012025155A1 WO 2012025155 A1 WO2012025155 A1 WO 2012025155A1 EP 2010062520 W EP2010062520 W EP 2010062520W WO 2012025155 A1 WO2012025155 A1 WO 2012025155A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
phenyl
hydroxy
acrylamide
ylmethyl
Prior art date
Application number
PCT/EP2010/062520
Other languages
English (en)
Inventor
Young Shin Cho
Lei Jiang
Michael Shultz
Christine Hiu-Tung Chen
Gang Liu
Jianke Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to PCT/EP2010/062520 priority Critical patent/WO2012025155A1/fr
Publication of WO2012025155A1 publication Critical patent/WO2012025155A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Definitions

  • deacetylation catalyzed by deacetylases, relates to transcriptional regulation of proteins involved in signal transduction. Accordingly, deacetylase inhibitors can be used for the therapy of pathological conditions or disorders wholly or in part mediated by one or more deacetylases. These conditions or disorders can include retinopathies, age-related macula degeneration, psoriasis, haemangioblastoma, haemangioma, arteriosclerosis, muscie wasting conditions such as muscular dystrophies, cachexia, Huntington ' s syndrome, inflammatory diseases such as rheumatoid or rheumatic inflammatory diseases, and neoplastic diseases.
  • deacetylase inhibitors can be useful for treating arthritis and arthritic conditions (e.g., osteoarthritis, rheumatoid arthritis, and the like), other chronic inflammator disorders (e.g., chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and the like), solid tumors (e.g., cancers of the gastrointestinal tract, pancreas, breast, stomach, cervix, bladder, kidney, prostate, esophagus, ovaries, endometrium, lung, brain, melanoma, Kaposi 's sarcoma, squamous cell carcinoma of head and neck, malignant pleural mesotherioma, lymphoma, multiple myeloma, and the like), and liquid tumors (e.g., leukemias).
  • arthritis and arthritic conditions e.g., osteoarthritis, rheumatoid arthritis, and the like
  • histone deacetylases remove an acetyl group from an N-acetyl lysine on a histone.
  • histone deacetylase (HDAC) and histone acetyltransferase together control the level of acetylation of histones to maintain a balance.
  • Reversible acetylation of histones is a major regulator of gene expression that acts by altering accessibi lity of transcription factors to DNA.
  • HDAC inhibitors have been studied for their therapeutic effect to proliferative diseases, including tumors, hyperprol iterative conditions, neoplasias, immune diseases, and central and peripheral nervous system diseases. More specifical ly, HDAC inhibitors can be useful for their antitumor activities.
  • proliferative diseases including tumors, hyperprol iterative conditions, neoplasias, immune diseases, and central and peripheral nervous system diseases. More specifical ly, HDAC inhibitors can be useful for their antitumor activities.
  • HDAC inhibitors can be useful for their antitumor activities.
  • HDAC inhibitors that have been studied for their anti-cancer activities include trichostatin A and trapoxin.
  • Trichostatin A an antifungal and antibiotic agent, is a reversible inhibitor of mammalian HDAC and trapoxin, a cyclic tetrapeptide, is an irreversible inhibitor of mammalian HDAC.
  • the present teachings also relate to methods of preparing compounds of Formula I, including pharmaceutically acceptable salts, hydrates, esters and prodrugs thereof, and methods of using compounds of Formula I, including pharmaceutically acceptable salts, hydrates, esters and prodrugs thereof, in treating pathologic conditions or disorders mediated wholly or in part by deacetylases, for example, including administering a therapeutically effective amount of a compound of Formula I to a patient, for example, a patient in need thereof.
  • pathologic conditions or disorders include undesired proliferative conditions, neurodegenerative diseases, cardiovascular diseases, strokes, autoimmune diseases, inflammatory diseases, undesired immunological processes, and fungal infections.
  • compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present teachings also consist essentially of, or consist of, the recited components, and that the processes of the present teachings also consist essentially of, or consist of, the recited process steps.
  • an element or component is said to be included in and/or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components and can be selected from a group consisting of two or more of the recited elements or components.
  • a "compound” refers to the compound itself and its pharmaceutically acceptable salts, hydrates, and esters, unless otherwise understood from the context of the description or expressly limited to one particular form of the compound, i.e., the compound itself, or a pharmaceutical ly acceptable salt, hydrate, or ester thereof.
  • halo or halogen refers to fluoro, chloro, bromo, and iodo.
  • o o refers to a double-bonded oxygen (i.e., -O).
  • alkyi refers to a straight-chain or branched saturated hydrocarbon group.
  • an alkyl group can have from I to 10 carbon atoms (e.g., from 1 to 6 carbon atoms).
  • alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, s-butyl, t-butyl), pentyl groups (e.g., n-pentyl, isopentyl, neopentyl), and the like.
  • alkyl groups optionaily can be substituted with up to four groups independently selected from -L-R 8 and -L-R i 3 , where L, R 8 , and R 1 3 are as described herein.
  • a lower alkyl group typically has up to 4 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl (e.g., n-propyl and isopropyl), and butyl groups (e.g., n-butyl, isobutyl, s-butyl, t-butyl).
  • alkenyi refers to a straight-chain or branched alkyl group having one or more carbon-carbon double bonds.
  • an alkenyi group can have from 2 to 10 carbon atoms (e.g., from 2 to 6 carbon atoms).
  • alkenyi groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl groups, and the like.
  • the one or more carbon-carbon double bonds can be internal (such as in 2-butene) or terminal (such as in 1 -butene).
  • alkenyi groups optionally can be substituted with up to four groups independently selected from -L-R and -L-R , where L, R , and R are as described herein.
  • alkynyl refers to a straight-chain or branched alkyl group having one or more carbon-carbon triple bonds.
  • an alkynyl group can have from 2 to 10 carbon atoms (e.g., from 2 to 6 carbon atoms).
  • alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, and the like.
  • the one or more carbon-carbon triple bonds can be internal (such as in 2-butyne) or terminal (such as in 1 -butyne).
  • alkynyl groups optionally can be substituted with up to four groups independently selected from -L-R s and -L-R 1 3 , where L, R 8 , and R 13 are as described herein.
  • alkoxy refers to an -O-alkyl group.
  • alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy groups, and the like.
  • >l aikylthio refers to an -S-alkyi group.
  • alkylthio groups include methylthio, ethylthio, propy!thio (e.g., n-propylthio and isopropylthio), t-butylthio groups, and the like.
  • haioalkyl refers to an alkyl group having one or more halogen substituents. In some embodiments, a haioalkyl group can have 1 to 10 carbon atoms (e.g., from I to 6 carbon atoms).
  • haioalkyl groups include CF 3 , C 2 Fs, CHF 2 , CH 2 F, CCI 3 , CHCI 2 , CH 2 CI, C2CI5, and the like.
  • Perhaloalkyl groups i.e., alkyl groups where all of the hydrogen atoms are replaced with halogen atoms (e.g., CF 3 and C 2 F 3 ⁇ 4 ), are included within the definition of
  • haioalkyl For example, a C
  • X is F, CI, Br, or I
  • i is an integer in the range of 1 to 10
  • j is an integer in the range of 0 to 21 , provided that j is less than or equal to 2i+ 1 .
  • cycloalkyi refers to a non-aromatic carbocyclic group including cyclized alkyl, alkenyl, and alkynyt groups.
  • a cycloalkyi group can be monocyclic (e.g., cyclohexyl) or poiycycl ic (e.g., containing fused, bridged, and/or spiro ring systems), where the carbon atoms are located inside or outside of the ring system.
  • a cycloalkyi group as a whole, can have from 3 to 14 ring atoms (e.g., from 3 to 8 carbon atoms for a monocyclic cycloalkyi group and from 7 to 14 carbon atoms for a poiycyclic cycloalkyi group). Any suitable ring position of the cycloalkyi group can be covalently linked to the defined chemical structure.
  • cycloalkyi groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyi, cyclohexenyl, cyclohexadienyi, cycloheptatrienyl, norbornyl, norpinyi, norcaryl, adamantyl, and spiro[4.5]decanyl groups, as well as their homologs, isomers, and the like.
  • cycloalkyi groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyi, cyclohexenyl, cyclohexadienyi, cycloheptatrienyl, norbornyl, norpinyi, norcaryl, adamantyl, and spiro[4.5]decanyl groups, as well
  • cycloalkyi groups optionally can be substituted with up to four groups
  • cycloalkyi groups can be substituted with one or more oxo groups.
  • heteroatom refers to an atom of any element other than carbon or hydrogen and includes, for example, nitrogen, oxygen, sulfur, phosphorus, and selenium.
  • cycloheteroalkyl refers to a non-aromatic cycloalkyi group that contains at least one (e.g., one, two, three, four, or five) ring heteroatom selected from O, N, and S, and optional ly contains one or more (e.g., one, two, or three) double or triple bonds,
  • cycioheteroalkyl group as a whole, can have from 3 to 14 ring atoms and contains from I to 5 ring heteroatoms (e.g., from 3-6 ring atoms for a monocyclic cycioheteroalkyl group and from 7 to 14 ring atoms for a poiycyclic cycioheteroalkyl group).
  • the cycioheteroalkyl group can be cov 1985ly attached to the defined chemical structure at any heteroatom(s) or carbon atom(s) that results in a stable structure.
  • N or S atoms in a cycloheteroalkyl ring may be oxidized (e.g., morpholine N-oxide, thiomorphotine S-oxide, thiomorpholine S,S-dioxide).
  • nitrogen atoms of cycloheteroalkyl groups can bear a substituent, for example, a -L- or -L-R group, where L, R , and R are as described herein.
  • Cycloheteroalkyl groups can also contain one or more oxo groups, such as phthalimidyl, piperidonyl, oxazolidinonyt, 2,4( I H,3H)-dioxo-pyrimidinyl, pyridin-2( l H)-onyl, and the l ike.
  • oxo groups such as phthalimidyl, piperidonyl, oxazolidinonyt, 2,4( I H,3H)-dioxo-pyrimidinyl, pyridin-2( l H)-onyl, and the l ike.
  • cycloheteroalkyl groups include, among others, morpholinyl, thiomorpholinyl, pyranyl, imidazoltdiny!, imidazolinyl, oxazoltdinyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, piperazinyl, and the like.
  • cycloheteroalkyl groups optionally can be substituted with up to four groups independently selected from -L-R and -L-R , where L, R l , and R are as described herein.
  • aryl refers to an aromatic monocyclic hydrocarbon ring system or a polycyciic ring system where at least one of the rings in the ring system is an aromatic hydrocarbon ring and any other aromatic rings in the ring system include only hydrocarbons.
  • a monocyclic aryl group can have from 6 to 14 carbon atoms and a polycyciic aryi group can have from 8 to 14 carbon atoms.
  • the aryl group can be covendingly attached to the defined chemical structure at any carbon atom(s) that result in a stable structure.
  • an aryl group can have only aromatic carbocyclic rings, e.g., phenyl, l -naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl groups, and the like.
  • an aryl group can be a polycyciic ring system in which at least one aromatic carbocyclic ring is fused (i.e., having a bond in common with) to one or more cycloalkyl or cyc!oheteroaikyl rings.
  • aryl groups include, among others, benzo derivatives of cyclopentane (i.e., an indanyl group, which is a 5,6-bicyclic cycloalkyl/aromatic ring system), cyclohexane (i.e., a tetrahydronaphth l group, which is a 6,6-bicyclic cycloalkyl/aromatic ring system), imidazoline (i.e., a
  • benzimidazol iny! group which is a 5,6-bicyclic eye I oheteroaiky l/aromatic ring system
  • pyran i.e., a chromenyi group, which is a 6,6-bicyclic cycloheteroalkyl/aromatic ring system
  • aryl groups include benzodioxanyi, benzodioxolyl, chromanyl, indolinyl groups, and the l ike.
  • heteroaryl refers to an aromatic monocyclic ring system containing at least one ring heteroatom selected from O, N, and S or a polycyc!ic ring system where at least one of the rings tn the ring system is aromatic and contains at least one ring heteroatom.
  • a heteroaryl group as a whole, can have from 5 to 14 ring atoms and contain 1 -5 ring heteroatoms.
  • heteroaryl groups can include monocyclic heteroaryl rings fused to one or more aromatic carbocyctic rings, non-aromatic carbocyclic rings, or non-aromatic cycloheteroalkyl rings.
  • the heteroaryl group can be covalently attached to the defined chemical structure at any heteroatom or carbon atom that results in a stable structure.
  • heteroaryl rings do not contain O-O, S-S, or S-0 bonds.
  • one or more N or S atoms in a heteroaryl group can be oxidized (e.g., pyridine N-oxide, thiophene S-oxide, thiophene S,S-dioxide).
  • heteroaryl groups include, for example, the 5-membered and 6-membered monocyclic and 5-6 bicyclic ring systems shown below:
  • T is O, S, NH, N-L-R 8 , or N-L-R ! 3 , where L, R 8 , and R 13 are as defined herein.
  • heteroaryl rings examples include pyrrolyl, furyi, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, isothiazolyl, thiazoly!, thiadiazolyl, isoxazolyl, oxazolyi, oxadiazolyl, indolyl, isoindolyl, benzofuryl, benzothienyl, quinolyl, 2-methylquinolyl, isoquinolyl, qumoxaiyl, quinazolyl, benzotriazolyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl.
  • benzoxadiazolyl benzoxazoiyl, cinnoitnyl, 1 H- indazolyl, 2H-indazolyl, indolizinyi. isobenzofuyl, naphthyridinyi, phthalazinyl, pteridinyl, purinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl, furopyridinyl, thienopyridinyl, pyridopyrimidinyt, pyridopyraziny!, pyridopyridazinyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl groups, and the like.
  • heteroaryt groups include 4,5,6,7- tetrahydroindolyl, tetrahydroquinolinyl, benzothienopyridinyl, benzofuropyridinyl groups, and the like.
  • heteroaryl groups can be substituted with up to four groups independently selected from -L-R 8 and -L-R 13 , where L, R 8 , and R 13 are as described herein.
  • the compounds of the present teachings can include a "divalent group" defined herein as a linking group capable of forming a covalent bond with two other moieties.
  • compounds described herein can include a divalent Cj.io alkyl group, such as, for example, a methylene group.
  • LG a 'leaving group
  • leaving groups include, but are not limited to, halide (e.g., CI, Br, I), azide (N 3 ), thiocyanate (SCN), nitro (N0 2 ), cyanate (CN), tosylate (toluenesulfonate, OTs), mesylate (methanesuifonate, OMs), brosylate (p-bromobenzenesulfonate, OBs), nosylate (4-nitrobenzenesulfonate, ONs), water (H 2 0), ammonia (NH3), and triflate
  • halide e.g., CI, Br, I
  • SCN thiocyanate
  • CN nitro
  • CN cyanate
  • tosylate toluenesulfonate
  • mesylate methanesuifonate, OMs
  • brosylate p-bromobenzenesul
  • substituents of compounds are disclosed in groups or in ranges. It is specifically intended that the description includes each and every individual subcombination of the members of such groups and ranges.
  • CMO alkyl is specifically intended to individually disclose Q, C 2 , C3, C4, C 5 , C 6 , C 7 , Cg, C9, C1 , C]-C,o, C
  • C4-C9 C 4 -Cg, C4-C7, Cf-Cfi, C4-C5, Cs-Cin, C5-C9, Cs-Cg, C5-C7, Cs-C f t, C -C10, C6-C9, Q,-Cg, C 6 -C 7 , C7-C10, C7-C9, C 7 -C 8 , Cg-Cio, Cs-Cg, and C9-C10 alkyl.
  • the term "5-14 membered heteroaryl group” is specifically intended to individually disclose a heteroaryl group having 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 5-14, 5-13, 5-12, 5-11,5-10, 5-9, 5-8, 5-7, 5-6, 6-14, 6-13, 6-12, 6-11.6-10, 6-9, 6-8, 6-7, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-14, 8-13,8-12,8-11,8-10, 8-9, 9-14, 9-13,9-12,9-11,9-10, 10-14, 10-13, 10-12, 10-11, 11-14, 11-13, 11-12, 12-14, 12-13, or 13-14 ring atoms; and the phrase "'optionally substituted with 1-4 groups” is specifically intended to individualiy disclose a chemical group that can include 0, 1 , 2, 3, 4, 0-4, 0-3, 0-2, 0- 1 , 1 -4, 1 -3, 1 -2, 2-4, 2-3, and 3-4 groups.
  • asymmetric atom also referred as a chiral center
  • some of the compounds can contain two or more asymmetric atoms or centers, which can thus give rise to optical isomers (enantiomers) and diastereomers (geometric isomers).
  • optical isomers and diastereomers in their respective enantiomerically pure forms (i.e., (+) and (-) stereoisomers), in racemic mixtures, and in other mixtures of the (+) and (-) stereoisomers, as well as pharmaceutically acceptable salts, hydrates, and esters thereof.
  • Optical isomers in pure form or in enantiomerically enriched mixture can be obtained by standard procedures known to those skilled in the art, which include, but are not limited to, chiral separation, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis.
  • the present teachings also encompass cis and trans-isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It is also understood that the present teachings encompass all possible regioisomers and mixtures thereof, which can be obtained in pure form or in substantially enriched mixture by standard separation procedures known to those skilled in the art, including, but are not limited to, column chromatography, thin- layer chromatography, simulated moving-bed chromatography, and high-performance liquid chromatography.
  • ⁇ is a) a single bond or b) a double bond
  • ring A including the nitrogen atom (N), is a 6- 14 membered cycloheteroalkyl group optionally substituted with 1 -5 R 4 groups;
  • R 1 is a) H, b) a CJ.JQ alkyl group, c) a C 2- io alkenyl group, d) a C 2- io alkynyl group, e) a C 3- j4 cycloa!kyl group, or f) a 3- 14 membered cycloheteroalkyi group, wherein each of b) - t) optionally is substituted with 1 -4 -L-R 8 groups;
  • R 2 and R 3 independently are a) H or b) halogen
  • each of k) - q) optionally is substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , or two R 4 groups, taken together with the atom to which each R 4 group is attached and any intervening ring atoms, form a) a C 3- H cycioalkyl group, b) a C 6 -H aryl group, c) a 3- 14 membered cycloheteroalkyi group, or d) a 5- 14 membered heteroaryl group, wherein each of a) - d) optionally is substituted with 1 -4 groups independently selected from R 8 and -L-R 8 ;
  • R 5 at each occurrence, is a) H, b) a C] -! 0 alkyl group, c) a C 2- 1 o alkenyl group, d) a C 2 - s o alkynyl group, t) a C3.14 cycioalkyl group, g) a Ce-n aryl group, h) a 3- 14 membered cycloheteroalkyi group, or i) a 5- 14 membered heteroaryl group, wherein each of b) - i) optionally is substituted with 1 -4 groups independently selected from R 8 and -L-R 8 ;
  • R 6 and R 7 at each occurrence, independently are a) H, b) -OR 9 , c) -NR 9 R 10 , d) -C(0)R 9 , e) -C(0)OR 9 , f) -C(0)N RV°, g) -S(0) M R 9 , h) a C 0 alkyl group, i) a C 2 ., 0 alkenyl group, j) a C 2 - ] o alkynyl group, k) a C 3 .
  • j4 cycioalkyl group 1) a C 1 aryl group, m) a 3- 14 membered cycloheteroalkyi group, or n) a 5- 14 membered heteroaryl group, wherein each of h) - n) optionally is substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , or
  • R 6 and R 7 taken together with the atom to which each group is attached, form a) a C 3 . I 4 cycioalkyl group, b) a Q.M aryl group, c) a 3- 14 membered cycloheteroalkyi group, or d) a 5- 14 membered heteroaryl group, each of which optionally is substituted with 1 -4 groups
  • R 8 and -L-R 8 independently selected from R 8 and -L-R 8 ;
  • R S at each occurrence, is a) halogen, b) -CN, c) -N0 2 , d) oxo, e) ⁇ N-L-R 9 ,
  • each of the C ⁇ o alkyl groups, the C 2- io alkenyl group, the C 2 -io alkynyl group, the C 3 ,s4 cycloalkyl group, the Ce-u aryl group, the 3-14 membered cycloheteroalkyl group, and the 5-14 membered heteroaryl group optionally is substituted with 1-4 groups independently selected from R 13 and-L-R !3 ;
  • R 9 and R 10 at each occurrence, independently are a) H, b) -OR 11 , c) -NR , ! R 12 , d) -C(0)R N , e) -C(0)OR' -C(0)NR' 'R 12 , g) -S(0) m R' h) a C M0 alky! group, i) a C 2 .
  • alkenyl group j) a C 2- io alkynyl group, k) a C 3- i4 cycloalkyl group, I) a C 6- i4 aryl group, m) a 3-14 membered cycloheteroalkyl group, or n) a 5-14 membered heteroaryl group, wherein each of h) - n) optionally is substituted with 1-4 groups independently selected from R 13 and -L-R 13 ;
  • R and R at each occurrence, independently are a) H, b) a CMO alkyl group, c) a C 2- io alkenyl group, d) a C 2-] o alkynyl group, e) a C 3-14 cycloalkyl group, f) a aryl group, g) a 3-14 membered cycloheteroalkyl group, or h) a 5-14 membered heteroaryl group, wherein each of b) - h) optionally is substituted with 1-4 groups independently selected from R 13 and -L-R 13 ;
  • R 13 at each occurrence, is a) halogen, b) -CN, c) -N0 2 , d) oxo, e) -OH, f) -NH 2 ,
  • L at each occurrence, is a) a divalent C O alkyl group, b) a divalent C 2- iu alkenyl group, c) a divalent C 2 -io alkynyl group, d) a divalent CMO haloalkyl group, e) a divalent CMO alkoxy group, or f) a cova!ent bond; and
  • n 0, 1 , or 2.
  • :r ⁇ can be a double bond.
  • the double bond can be a cis-doubie bond ⁇ i.e., a Z-double bond) or a trans- double bond (i.e., an E-doubie bond).
  • a trans-double bond i.e., an E-doubie bond.
  • compounds of the present teachings can have Formula la or Formula lb:
  • R 2 , and R 3 are as defined herein.
  • ring A including the nitrogen atom, can be a 6- 12 membered cycloheteroalkyi group optionally substituted with 1 -4 R 4 groups, where R 4 is as defined herein.
  • the 6- 12 membered cycloheteroalkyi group can have 1 , 2, 3, or 4 ring atoms independently selected from N, O, and S.
  • ring A, including the nitrogen atom can be a six-membered cycloheteroalkyi group having 1 -2 ring atoms independently selected from N, O, and S, where the six-membered cycloheteroalkyi group optionally can be substituted with 1 -4 R 4 groups and R 4 is as defined herein.
  • ring A can be selected from:
  • ring A can be selected from i, Hi, v, and vii, each of which optionally can be substituted with 1 -4 R 4 groups, where R 4 is as defined herein.
  • R 4 group is attached and any intervening ring atoms, can form a C6-M aryl group, a 3- 14 membered cycloheteroalkyl group, or a 5- 14 membered heteroaryl group, where each of the Q-M aryl group, the 3- 14 membered cycloheteroalkyt group, and the 5- 14 membered heteroaryl group optionally can be substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , where L and R 8 are as defined herein.
  • two R 4 groups taken together with the common atom to which the two R 4 groups are attached and any intervening ring atoms, can form a C -I 4 aryl group, a 3- 14 membered cycloheteroalkyl group, or a 5- 14 membered heteroaryl group, where each of the C 6 -i 4 aryl group, the 3- 14 membered cycloheteroalkyl group, and the 5- 14 membered heteroaryl group optionally can be substituted with 1 -4 groups independently selected from R K and -L-R 8 , where L and R s are as defined herein.
  • the C6-H aryl group, the 3- 14 membered cycloheteroalkyl group, or the 5- 14 membered heteroaryl group can be selected from:
  • each of viii - xii optionally can be substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , where L and R 8 are as defined herein.
  • two R 4 groups taken together with two atoms to which the two R 4 groups respectively are attached and any intervening ring atoms, can form a €5- 14 aryl group, a 3- 14 membered cycloheteroalkyi group, or a 5- 14 membered heteroaryl group, where each of the C 6 - i 4 aryl group, the 3- 14 membered cycloheteroalkyi group, and the 5- 14 membered heteroaryl group optionally can be substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , where L and R 8 are as defined herein.
  • 4 aryl group, the 3- 14 membered cycloheteroalkyi group, or the 5- 14 membered heteroaryl group can be selected
  • R 6 and R 7 taken together w ith the carbon atom to w hich they are attached, can form a 5- 14 membered heteroaryl group optionally substituted w ith 1 -4 groups independently selected from R 8 and -L- 8 , where L and R S are as defined herein.
  • ring A optionally can be substituted with:
  • ring A optionally can be substituted with 1 -4 groups independently selected from -C(0)R 5 , -C(0)OR 6 , ⁇ C(0)NR 6 R 7 and -S0 2 R 5 , where R 5 , R 6 , and R 7 are as defined herein.
  • ring A optionally can be substituted with 1 -4 groups independently selected from -C(0)R 5 , -C(0)OR 6 , -C(0)NR 6 R 7 and -S0 2 R 5 , where R 5 , R 6 , and R , at each occurrence, independently can be a C
  • R 5 and R 6 at each occurrence, independently can be C alkyl, C3.6 cycloalkyl, benzyl, or phenyl optionally substituted with one methyl or fluoro group, and R 7 is H.
  • ring A optionally can be substituted with 1 -4 groups independently selected from a C M O alkyl group, a C 6- i 4 aryl group, a 3- 14 membered cycloheteroalkyl group, and a 5- 14 membered heteroaryl group, where each of the C M 0 alkyl groups, the C 6- ] 4 aryl group, the 3- 14 membered cycloheteroalkyl group, and the 5- 14 membered heteroaryl group optionally can be substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , where L and R 8 are as defined herein.
  • ring A optionally can be substituted with 1 -4 groups independently selected from a methyl group, an ethyl group, a propyl group, and a benzyl group, each of which optionally can be substituted with 1 -4 groups independently selected from R 8 and -L-R 8 , where L and R 8 are as defined herein.
  • ring A optionally can be substituted with 1 or 2 groups each independently selected from the group consisting of a methyl group, an ethyl group, a propyl group, a (CH3)C 0)CH 3 group, a CH 2 CfO)NHOH group, a benzyl group , and a 4-bromobenzyl group.
  • ring A optionally can be substituted with 1 -4 groups independently selected from a C ⁇ s-i 4 ary' grou , a 5- 10 membered cycloheteroalkyl group, and a 5- 10 membered heteroaryl group, each of which optionally can be substituted with 1 -4 groups independently selected from R and -L-R 8 , where L and R 8 are as defined herein.
  • the C 6 .] aryl group, the 5- 10-membered cycloheteroalkyl group, or the 5- 10 membered heteroaryl group can be selected from a phenyl group, an imtdazolidyi group, an isoxazolyl group, an oxadiazolyl group, a pyridyl group, an indolyl group, an indoliny! group, a benzofuranyl group, a tetrahydroisoquinoiyl group, a l H-benzoimidazolyl group, and a benzopyridyl group.
  • phenyl group, imidazolidyl group, isoxazolyl group, oxadiazolyl group, pyridyl group, indolyl group, indotinyl group, benzofuranyl group, tetrahydroisoquinoiyl group, 1 H- benzoimidazolyl group, and benzopyridyl group can be substituted with one or two substituents each independently selected from the group consisting of C M aikyl otionally substituted by one hydroxy group; isobutenyl, C 3 ⁇ cycloalkyl, phenyl, morpholinyl, oxo, C(0)C H 5 ,
  • R 2 and R 3 can independently be selected from H, F, CI, and Br. In some embodiments, R 2 and R 3 can independently be selected from H, F, and CI. In some embodiments R 2 and R 3 are both hydrogen. In other embodiments R 2 is hydrogen and R 3 is fiuoro or chloro.
  • R 1 can be H, a C O aikyl group, a C3.14 cycloalkyl group, or a 3- 14 membered cycloheteroalkyl group, where each of the C
  • R L can be H, a Q.io aikyl group, or a C3.14 cycloalkyl group, where each of the C i - S o aikyl group and a C 3 .
  • R 1 can be H.
  • R 1 can be a methyl group, an ethyl group, an isopropyl group, a t-butyl group, a cyclopropyl group, a cyclopentyl group, or a cyclohexyl group, each optionally substituted with 1 -4 groups independently selected from halogen.
  • Compounds of the present teachings can be selected from the compounds in Table 1.
  • prodrugs of the compounds disclosed herein refers to a compound ("parent compound * ') having a moiety that produces, generates, or releases a compound of the present teachings ("active compound”) when administered to a mammalian subject.
  • Prodrugs can be prepared by modifying functional groups present in the active compounds in such a way that the modifications can be removed, either by routine manipulation or in vivo, from the parent compounds.
  • prodrugs include compounds that contain one or more molecular moieties that are appended to a hydroxyl, amino, sulfhydryl, or carboxyl group of the active compounds, and that, when administered to a mammalian subject, is/are cleaved in vivo to form the free hydroxyl, amino, sulfhydryl, or carboxyl group, respectively, and to release the active compound.
  • prodrugs can include acetate, formate, and benzoate derivatives of hydroxy and amino functional groups in the compounds of the present teachings. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems, " ' Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, the entire disclosures of which are incorporated by reference herein for all purposes.
  • Ester forms of the compounds according to the present teachings include pharmaceutically acceptable esters known in the art that can be metabolized into the free acid form, such as a free carboxylic acid form, in a mammal body.
  • esters include alkyl esters (e.g., aikyls of 1 to 10 carbon atoms), cycloalkyl esters (e.g., cycloalkyls of 3- 10 carbon atoms), aryl esters (e.g., aryls of 6- 14 carbon atoms, including of 6- 10 carbon atoms), and heterocyclic analogues thereof (e.g., heterocyclics of 3- 14 ring atoms, 1 -3 of which can be selected from O, N, and S) and the alcoholic residue can carry further substituents.
  • alkyl esters e.g., aikyls of 1 to 10 carbon atoms
  • cycloalkyl esters e.g., cycloalkyls of 3- 10
  • esters of the compounds disclosed herein can be C O alkyl esters, such as methyl esters, ethyl esters, propyl esters, isopropyl esters, butyi esters, isobutyl esters, t-butyl esters, pentyl esters, isopentyl esters, neopentyl esters, hexyl esters, cyclopropylmethyl esters, and benzyl esters, C 3 _io cycloalkyl esters, such as cyclopropyl esters, cyclobutyl esters, cyclopentyl esters, and cyclohexyl esters, or aryl esters, such as phenyl esters and tolyl ester.
  • C O alkyl esters such as methyl esters, ethyl esters, propyl esters, isopropyl esters, butyi esters, isobutyl esters, t-but
  • salts of compounds of the present teachings can be formed using organic or inorganic bases. Both mono and polyanionic salts are contemplated, depending on the number of acidic hydrogens available for deprotonation.
  • Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, fhiomorpholine, piperidine, pyrrolidine, a mono-, di-, or tri-iower a!kylamine (e.g., ethyl-tert-butylamine, diethyiamine, diisopropylamine, triethylamine, tributylamine, or dimethylpropylamine), or a mono-, di-, or trihydrox lower alkylamine (e.g., mono-, di- or triethano!amine).
  • metal salts such as alkali
  • Non-limiting examples of inorganic bases include Nal 1C0 3 , Na 2 C0 3 , HC0 3 , 2 C0 3 , Cs 2 C0 3 , LiOH, NaOH, OH, NaH 2 P0 , Na 2 HP0 4 , and Na 3 P0 4 .
  • Internal salts also can be formed.
  • salts can be formed using organic and inorganic acids.
  • salts can be formed from any of the following acids: acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, dichloroacetic, ethenesulfonic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, malonic, mandelic, methanesulfonic, mucic, napthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, phthal ic, propionic, succinic, sulfuric, tartaric, toluenesulfonic, as well as other known pharmaceutically acceptable acids.
  • the present teachings provide pharmaceutical compositions including at least one compound described herein and one or more pharmaceutically acceptable carriers, excipients, or diluents.
  • pharmaceutically acceptable carriers are well know n to those skilled in the art and can be prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in Remington: The Science and Practice of Pharmacy, 20th edition, Alfonoso . Gennaro (ed.), Lippincott Williams & Wilkins, Baltimore, MD (2000), the entire disclosure of which is incorporated by reference herein for all purposes.
  • ''pharmaceutically acceptable refers to a substance that is acceptable for use in pharmaceutical applications from a toxicoiogical perspective and does not adversely interact with the active ingredient.
  • pharmaceutical ly acceptable carriers are those that are compatible with the other ingredients in the formulation and are biologically acceptable.
  • Supplementary active ingredients can also be incorporated into the pharmaceutical compositions.
  • Compounds of the present teachings can be useful for inhibiting a deacetylase in a cell.
  • another aspect of the present teachings includes a method of contacting a cell with one or more compounds of the present teachings (or a salt, hydrate, ester, or prodrug thereof) or a composition that includes one or more compounds of the present teachings, in certain embodiments, the composition can further include one or more pharmaceutically acceptable carrier or excipients.
  • Compounds of the present teachings can be useful for the treatment, inhibition, prevention, or diagnosis of a pathological condition or disorder in a mammal, for example, a human.
  • another aspect of the present teachings includes a method of providing to a mammal a compound of the present teachings (or its pharmaceutically acceptable salt, hydrate, ester, or prodrug) or a pharmaceutical composition that includes one or more compounds of the present teachings in combination or association with a pharmaceutically acceptable carrier.
  • Compounds of the present teachings can be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment, inhibition, prevention, or diagnosis of the pathological condition or disorder.
  • therapeutically effective refers to a substance or an amount that elicits a desirable biological activity or effect.
  • the present teachings can further include use of the compounds disclosed herein as active therapeutic substances for the treatment or inhibition of a pathological condition or disorder, for example, a condition mediated whol ly or in part by one or more deacetylases, such as an undesired proliferative condition; a neurodegenerative disease, including Alzheimer's disease, Hungtirtgton's disease, Rubenstein-Taybis syndrome, Parkinson's disease, muscular dystrophy, spinal muscular atrophy, Rett's syndrome, and the like; a cardiovascular disease, including heart failure, cardiac hypertrophy, thrombosis, and the like; an autoimmune disease, including Lupus, atherosclerosis, scleroderma, and the like; an inflammatory disorder, including arthritis and arthritic conditions (e.g., osteoarthritis, rheumatoid arthritis, and the like), and other chronic inflammatory disorders (e.g., chronic asthma, arterial or post-transplantational atherosclerosis, endometri
  • the undesired proliferative condition includes a cancer (e.g., brain cancer, kidney cancer, liver cancer, adrenal gland cancer, bladder cancer, breast tumor, stomach cancer including gastric tumors, esophagus cancer, ovarian cancer, colon cancer, rectum cancer, prostate cancer, pancrea cancer, lung cancer including smalt cell lung cancer, vagina cancer, thyroid cancer, sarcoma, glioblastomas, multiple myeloma, gastrointesti al cancer, lung cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer), a tumor, a fibrosis, and the like; a neoplasia, including mammary carcinoma, leukemia, and the like; and an epidermal hyperproliferation, including psoriasis, prostate hyperplasia, and the like.
  • a cancer e.g., brain cancer, kidney cancer, liver cancer, adrenal gland cancer, bladder cancer, breast tumor, stomach cancer including gastric tumors, esophagus cancer, ova
  • the present teachings can provide methods of treating these pathological conditions and disorders using the compounds described herein.
  • treating refers to partially or completely alleviating and/or ameliorating the condition or symptoms thereof.
  • the methods can include identifying a mammal having a pathological condition or disorder mediated by deacetylases, and providing to the mammal a therapeutically effective amount of a compound as described herein.
  • the method can include administering to a mammal a pharmaceutical composition that can include a compound disclosed herein in combination or association with a pharmaceutically acceptable carrier.
  • the present teachings can further include use of the compounds disclosed herein as active therapeutic substances for the prevention of a pathological condition or disorder, for example, a condition mediated wholly or in part by one or more deacetylases, such as an undesired proliferative condition; a neurodegenerative disease, including Alzheimer's disease, Hungtington's disease, Rubenstein-Taybis syndrome, Parkinson's disease, muscular dystrophy, spinal muscular atrophy, Rett's syndrome, and the l ike; a cardiovascular disease, including heart failure, cardiac hypertrophy, thrombosis, and the like; an autoimmune disease, including Lupus, atherosclerosis, scleroderma, and the like; an inflammatory disorder, including arthritis and arthritic conditions (e.g., osteoarthritis, rheumatoid arthritis, and the like), and other chronic inflammatory disorders (e.g., chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and the
  • the undesired proliferative condition includes a cancer (e.g., brain cancer, kidney cancer, liver cancer, adrenal gland cancer, bladder cancer, breast tumor, stomach cancer including gastric tumors, esophagus cancer, ovarian cancer, colon cancer, rectum cancer, prostate cancer, pancrea cancer, lung cancer including small cell lung cancer, vagina cancer, thyroid cancer, sarcoma, glioblastomas, multiple myeloma, gastrointestinal cancer, lung cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer), a tumor, a fibrosis, and the like; a neoplasia, including mammary carcinoma, leukemia, and the like; and an epidermal hyperproliferation, including psoriasis, prostate hyperplasia, and the like.
  • a cancer e.g., brain cancer, kidney cancer, liver cancer, adrenal gland cancer, bladder cancer, breast tumor, stomach cancer including gastric tumors, esophagus cancer, ovarian cancer, colon cancer
  • the present teachings can provide methods of preventing these pathological conditions and disorders using the compounds described herein.
  • the methods can include identifying a mammal that could potentially have a pathological condition or disorder mediated by deacetylases, and providing to the mammal a therapeutically effective amount of a compound as described herein.
  • the method can include administering to a mammal a pharmaceutical composition that can include a compound disclosed herein in combination or association with a pharmaceutically acceptable carrier.
  • Cardiac hypertrophy in response to an increased workload imposed on the heart is a fundamental adaptive mechanism. It is a specialized process reflecting a quantitative increase in cell size and mass (rather than cel l number) as the result of any or a combination of neural, endocrine or mechanical stimuli.
  • Hypertension another factor involved in cardiac hypertrophy, is a frequent precursor of congestive heart failure. When heart failure occurs, the left ventricle usually is hypertrophied and dilated and indices of systolic function, such as ejection fraction, are reduced.
  • the cardiac hypertrophic response is a complex syndrome and the elucidation of the pathways leading to cardiac hypertrophy wi ll be beneficial in the treatment of heart disease resulting from a various stimuli.
  • a method of preventing pathologic cardiac hypertrophy and heart failure with the compopunds of the present invention includes administering to the patient a histone deacetylase inhibitor.
  • Administration may comprise intravenous, oral, transdermal, sustained release, suppository, or sublingual administration.
  • the patient at risk may exhibit one or more of long standing uncontrolled hypertension, uncorrected valvular disease, chronic angina and/or recent myocardial infarction.
  • treatment comprises reducing one or more of the symptoms of cardiac hypertrophy, such as reduced exercise capacity, reduced blood ejection volume, increased left ventricular end diastolic pressure, increased pulmonary capillary wedge pressure, reduced cardiac output, cardiac index, increased pulmonary artery pressures, increased left ventricular end systolic and diastolic dimensions, and increased left ventricular wail stress, wall tension and wall thickness-same for right ventricle.
  • use of HDAC inhibitors may prevent cardiac hypertrophy and its associated symptoms from arising.
  • Treatment regimens would vary depending on the clinical situation. However, long term maintenance would appear to be appropriate in most circumstances. It also may be desirable treat hypertrophy with HDAC inhibitors intermittently, such as within brief window during disease progression. At present, testing indicates that the optimal dosage for an HDAC inhibitor will be the maximal dose before significant toxicity occurs.
  • an HDAC inhibition in combination with other therapeutic modalities.
  • standard therapies include, without limitation, so-called “beta blockers,” anti-hypertensives, cardiotonics, antithrombotics, vasodilators, hormone antagonists, iontropes, diuretics, endothelin antagonists, calcium channel blockers, phosphodiesterase inhibitors, ACE inhibitors, angiotensin type 2 antagonists and cytokine blockers/inhibitors.
  • the cardiovascular indications for which the HDAC inhibitors may be used include: diastolic dysfunction, myocardial Infarction (systolic dysfunction), inhibition of overall cardiac remodeling in both acute and chronic heart fai lure conditions, adriamycin induced cardiotoxicity, inducing cardioprotection from ischemic events, and for the use of hemorrhagic shock and resuscitation.
  • Compounds of the present teachings can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers.
  • Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents, or encapsulating materials.
  • the compounds can be formulated in conventional manner, for example, in a manner similar to that used for known HDAC inhibitors.
  • Oral formulations containing an active compound disclosed herein can include any conventionally used oral form, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions, and solutions, in powders, the carrier can be a finely divided solid, which is an admixture with a finely divided active compound.
  • an active compound in tablets, can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets may contain up to 99% of the active compound.
  • Capsules can contain mixtures of active compound(s) optionally with inert filler(s) and/or diluent(s) such as the pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.
  • inert filler(s) and/or diluent(s) such as the pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.
  • Useful tablet formulations can be made by conventional compression, wet granulation or dry granuiation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending agents, or stabilizing agents, including magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cel lulose, microcrystal line cellulose, sodium
  • Preferred surface modifying agents include nonionic and anionic surface modifying agents.
  • Representative examples of surface modifying agents include poloxamer 1 88, benzalkonium chloride, calcium stearate, cetostearl alcohol,
  • cetomacrogol emulsifying wax sorbttan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine.
  • Oral formulations herein can utilize standard delay or time-release formulations to alter the absorption of the active compound(s).
  • the oral formulation can also consist of administering an active compound in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed.
  • Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups, and elixirs.
  • An active compound described herein can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture thereof, or pharmaceutically acceptable oils or fats.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-reguiators.
  • liquid carriers for oral and parenteral administration include water (particularly containing additives as described above, e.g., cellulose derivatives such as a sodium
  • the carrier can be an oily ester such as ethyl oieate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
  • the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal, or subcutaneous injection. Sterile solutions can also be administered intravenously.
  • Compositions for oral administration can be in either liquid or solid form.
  • the pharmaceutical composition can be in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories.
  • the pharmaceutical composition can be sub-divided in unit dose(s) containing appropriate quantities of the active compound.
  • the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilied syringes or sachets containing liquids.
  • the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • Such unit dosage form may contain from about 1 mg/kg of active compound to about 500 mg/kg of active compound, and can be given in a single dose or in two or more doses.
  • Such doses can be administered in any manner useful in directing the active compound(s) to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.
  • Such administrations can be carried out using the compounds of the present teachings including pharmaceutically acceptable salts, hydrates, and esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
  • an effective dosage can vary depending upon the particular compound utilized, the mode of administration, and/or severity of the condition being treated, as well as the various physical factors related to the individual being treated.
  • a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications.
  • a compound of the present teachings can be provided to a patient that can suffer from a disease in an amount sufficient to prevent or at least delay the symptoms of the disease and its complications.
  • the dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician. The variables involved include the specific condition and its state as well as the size, age and response pattern of the patient.
  • the lung is the targeted organ
  • the compounds of the present teachings can be formulated into a liquid composition, a sol id composition, or an aerosol composition.
  • the liquid composition a sol id composition, or an aerosol composition.
  • composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser.
  • the solvents can be, for example, isotonic saline or bacteriostatic water.
  • the solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation.
  • the aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device.
  • the propellants can be a
  • chlorofluorocarbon CFC
  • HFA hydrofluoroalkane
  • compositions described herein can be administered parenterally or intraperitoneal ly.
  • Solutions or suspensions of these active compounds or pharmaceutically acceptable salts, hydrates, or esters thereof can be prepared in water mixed with a suitable surfactant such as hydroxyl- propylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms.
  • the pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form is sterile and its viscosity permits it to flow through a syringe.
  • the form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • Compounds of the present teachings can be administered transdermal !y, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administration can be carried out using the compounds of the present teachings including pharmaceutical ly acceptable salts, hydrates, or esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal). Topical formuJations that deliver active compound(s) through the epidermis can be useful for localized treatment of a pathologic condition or disorder.
  • Transdermal administration can be accomplished through the use of a transdermal patch containing an active compound and a carrier that can be inert to the active compound, can be non-toxic to the skin, and can allow del ivery of the active compound for systemic absorption into the blood stream via the skin.
  • the carrier can take any number of forms such as creams, ointments, pastes, gels, and occlusive devices.
  • the creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active compound can also be suitabie.
  • occlusive devices can be used to release the active compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the active compound with or without a carrier, or a matrix containing the active compound.
  • Other occlusive devices known in the literature are also contemplated.
  • Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin.
  • Water-soluble suppository bases such as polyethylene glycols of various molecular weights, can also be used.
  • Lipid formulations or nanocapsules can also be used to introduce compounds of the present teachings into host cells either in vitro or in vivo.
  • Lipid formulations and nanocapsules can be prepared by methods known in the art.
  • a compound disclosed herein can be combined with other agents effective in the treatment of the target disease.
  • other active compounds i.e., other active ingredients or agents
  • active compounds of the present teachings can be administered with active compounds of the present teachings.
  • the other agents can be administered at the same time or at different times than the compounds disclosed herein.
  • the compounds of the present teachings can be prepared in accordance with the procedures outlined in the scheme below, from commercial ly available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art.
  • Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented may be varied for the purpose of optimizing the preparation of the compounds described herein.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ⁇ or , C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatograpy (HPLC), gas chromatograph (GC), or thin layer chromatography.
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., ⁇ or , C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry
  • chromatography such as high performance liquid chromatograpy (HPLC), gas chromatograph (GC), or thin layer chromatography.
  • Preparation of compounds can involve the protection and deprotection of various chemical groups.
  • the need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by one skilled in the art.
  • the chemistry of protecting groups can be found, for example, in Greene, et aL, Protective Groups in Organic Synthesis, 4th Ed., Wiley & Sons, 2006, the entire disclosure of which is incorporated by reference herein for all purposes.
  • Suitable solvents typically are
  • Example 1 preparation of 4-[4-((E)-2-methoxycar onyI-vinyl)- enzyl]-piperazine-l- carboxylic acid tert-butyl ester
  • the residue is purified by a silica gel column chromatography ( 10-40% ethyl acetate/heptanes) to provide 4-[4-((E)-2-methoxycarbonyt-vinyl)-benzyl] -piperazine- 1 - carboxylic acid r/-butyl ester as a white solid ( 10.2 g).
  • Example 2 preparation of 4-[4 ⁇ ((E)-2-hydroxycarbamoyl-vinyl)-benzyl]-piperazine-l- carboxylic acid tert-butyl ester (1)
  • reaction mixture is diluted with dichloromethane (300 mL), washed with water ( 100 mL), brine ( 100 mL), dried over magnesium sulfate, filtered, and concentrated, and the residue is purified to give l -(4-bromo-benzyl)-5-(2-methyl- l H-indol-3-yl)-piperidin-3-one ( 199 mg, 1 7% yield over two steps).
  • Example 15 preparation of (E)-3-(3-fIuoro-4- ⁇ 3-[2-(l-hydroxy-l-methyI-ethyl)-lH-indol-3- yl]-piperidin-l-ylmethyl ⁇ -phenyI)-N-hydroxy-acrylamide (13)
  • N-hydroxy-3- ⁇ 4-[3-(2- phenyl- ] H-indol-3-yl)-piperidin- l -ylmethyl]-phenyl ⁇ -propionaniide is prepared from 2-phenyl- l H-indole and l -bromo-4-bromomethyl-benzene.
  • Example 19 preparation of 3- ⁇ l-l2-fluoro- -((E)-2- ydroxycarbamoyl-vinyl)-benzyl]- piperidin-3-yl ⁇ -lH-indole-2-carboxylic acid ethyl ester (17)
  • reaction mixture is treated with a saturated aqueous sodium bicarbonate ( 100 mL) and extracted with dichloromethane (3 X 100 mL).
  • dichloromethane 3 X 100 mL
  • the combined organics are dried over magnesium sulfate, filtered and concentrated in vacuo, and the residue is purified via a silica gel column
  • ketooxime 2- ⁇ 3-[(Z)-hydroxyimino]-3-pheny ⁇ - opion l ⁇ -mo ⁇ holine- 4-carboxylic acid /er/-butyl ester (655 mg, 1.88 mmol) in dichloromethane (25 mL) is cooled to 0°C and treated with triethylamine (0.80 mL, 5.75 mmol) and methanesulfony! chloride
  • Example 30 preparation of 4-[4-((E)-2-hydroxycarbamoyl-vinyl)-benzyl]-piperazine-l- carboxylic acid ethyl ester (28)
  • Example 31 preparation of 4-[4-((E)-2-hydroxycarbamoyl-vinyl)-benzyl]-piperazine-l- carboxylic acid benzyl ester (29)
  • Example 48 preparation of (E)-N-hydroxy-3- ⁇ 4-[4-(10-oxo-9,1 -dihydro-l-thia- benzo[fjazulen-4-ylidene)-piperidin-l -ylmethyl)-phenyl ⁇ -acrylamide (46)
  • Example 52 typical procedure for the formation of amide, sulfonamide and urea derivatives of (E)-3-(4-piperazin-l-ylmethyl-phenyl)-acrylic acid methyl ester
  • Step A preparation of (E)-3-(4-piperazin-l-ylmethyl-phenyl)-acrylic acid methyl ester
  • Step B preparation of amide, sulfonamide and urea derivatives of (E)-3-(4-piperazin-l- ylmethvi-phenvQ-acrvKc acid methyl ester
  • the baculovirus donor vector pFB-GSTX3 is used to generate a recombinant baculovirus that can express the HDAC polypeptide.
  • Transfer vectors containing the HDAC coding region are transfected into the DH l OBac cell line (G1BCO) and plated on selective agar plates. Colonies without insertion of the fusion sequence into the viral genome (carried by the bacteria) are blue. Single, white colonies are picked and viral DNAs (bacmid) are isolated from the bacteria by standard plasmid purification procedures. Sf9 cells or Sf2 l (American Type Culture Collection) cells are then transfected in 25 cm 3 flasks with the viral DNA using Cellfectin reagent.
  • Virus-containing media is collected from the transfected cell culture and used for infection to increase its titer. Virus- containing media obtained after two rounds of infection is used for large-scale protein expression. For large-scale protein expression 100 cm ' round tissue culture plates are seeded with 5 x 10 7 cells/plate and infected with 1 mL of virus-containing media (at an approximately MOI of 5). After 3 days, the cells are scraped off the plate and centrifuged at 500 rpm for 5 minutes. Cel l pellets from 10-20, 1 00 cm 2 plates, are re-suspended in 50 mL of ice-cold lysis buffer (25 mM tris-HCi, pH 7.5.
  • ice-cold lysis buffer 25 mM tris-HCi, pH 7.5.
  • the centrifuged cell lysate is loaded onto a 2 mL glutathione-sepharose column (Pharmacia) and is washed thrice with 10 mL of 25 mM tris-HCl, pH 7.5, 2 mM EDTA, 1 mM DTT, 200 mM NaCI.
  • the GST-tagged proteins are then eluted by 10 applications ( 1 mL each) of 25 mM tris-HCl, pH 7.5, 10 mM reduced-glutathione, 100 mM NaCI, 1 mM DTT, 10% glycerol and stored at -70°C.
  • HDAC assays with purified GST-HDAC protein are carried out in a final volume of 30 ⁇ containing 15 ng of GST-HDAC protein, 20 mM tris-HCl, pH 7.5, I mM MnCl 2 , 10 mM MgCl 2 , 1 mM DTT, 3 ⁇ ⁇ poly(Glu,Tyr) 4: 1 , 1 % DMSO, 2.0 ⁇ ATP ( ⁇ -[ 33 ⁇ ]- ⁇ 0. 1 ⁇ ).
  • the activity is assayed in the presence or absence of inhibitors.
  • the assay is carried out in 96- well plates at ambient temperature for 15 minutes under conditions described below and terminated by the addition of 20 ⁇ ] ⁇ of 125 mM EDTA.
  • IC50 values are calculated by logarithmic regression analysis of the percentage inhibition of each compound at 4 concentrations (usually 3- or 10-fold dilution series starting at 10 ⁇ ). In each experiment, the actual inhibition by reference compound is used for normalization of IC50 values to the basis of an average value of the reference inhibitor:
  • HDAC inhibitors or a synthetic derivative thereof may be used as reference compounds.
  • the compounds of the present teachings are found to show 1C50 values for HDAC inhibition in the range from about 0.0008 ⁇ to about 100 ⁇ , or about 0.0008 ⁇ to about 50 ⁇ , including, for example, the range from about 0.0008 ⁇ to about 2 ⁇ or less.
  • Table 2 provides assay results of exemplified compounds.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) ainsi que des sels, hydrates, esters et promédicaments pharmaceutiquement acceptables de tels composés. Dans la formule (I), R1, R2, R3, le cycle A et la (formule 2) sont tels que définis dans la présente. L'invention concerne également des procédés de préparation des composés de formule (I) ainsi que des procédés d'utilisation de tels composés pour traiter, inhiber ou prévenir des états pathologiques ou des troubles dus en partie ou en totalité aux désacétylases.
PCT/EP2010/062520 2010-08-26 2010-08-26 Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases WO2012025155A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/062520 WO2012025155A1 (fr) 2010-08-26 2010-08-26 Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/062520 WO2012025155A1 (fr) 2010-08-26 2010-08-26 Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases

Publications (1)

Publication Number Publication Date
WO2012025155A1 true WO2012025155A1 (fr) 2012-03-01

Family

ID=43731825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/062520 WO2012025155A1 (fr) 2010-08-26 2010-08-26 Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases

Country Status (1)

Country Link
WO (1) WO2012025155A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102875479A (zh) * 2012-10-24 2013-01-16 南京化工职业技术学院 喹唑啉二酮衍生物及其制备方法、其药物组合物及用途
JP2014526438A (ja) * 2011-06-28 2014-10-06 フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド 抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
CN105859695A (zh) * 2016-05-20 2016-08-17 苏州大学 2-芳基-3-(4-羟基-2h-吡喃-2-酮-3-基)吲哚衍生物及其合成方法
CN106008477A (zh) * 2016-06-02 2016-10-12 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法
CN106008476A (zh) * 2016-05-27 2016-10-12 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基香豆素衍生物及其合成方法
WO2017191130A2 (fr) 2016-05-04 2017-11-09 Oncoarendi Therapeutics Sa Inhibiteurs d'arginase et leurs applications thérapeutiques
WO2021154997A1 (fr) * 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leurs méthodes d'utilisation
CN115417877A (zh) * 2022-09-20 2022-12-02 杭州师范大学 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用
US11801234B2 (en) 2020-03-06 2023-10-31 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
US11866446B2 (en) 2020-08-26 2024-01-09 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2024012554A1 (fr) * 2022-07-14 2024-01-18 上海日馨医药科技股份有限公司 Agoniste de tpk et procédé de traitement de maladies neurodégénératives l'utilisant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (fr) * 2000-09-01 2002-03-21 Novartis Ag Inhibiteurs de desacetylase
WO2008040934A1 (fr) * 2006-10-06 2008-04-10 Chroma Therapeutics Ltd. Inhibiteurs de hdac
WO2009137462A2 (fr) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Procédés de traitement de troubles cognitifs à l'aide d'inhibiteurs de l'histone désacétylase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (fr) * 2000-09-01 2002-03-21 Novartis Ag Inhibiteurs de desacetylase
WO2008040934A1 (fr) * 2006-10-06 2008-04-10 Chroma Therapeutics Ltd. Inhibiteurs de hdac
WO2009137462A2 (fr) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Procédés de traitement de troubles cognitifs à l'aide d'inhibiteurs de l'histone désacétylase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
GREENE: "Protective Groups in Organic Synthesis", 2006, WILEY & SONS
SYNTHESIS, 1974, pages 354 - 356
T. HIGUCHI I; V. STCLLA: "Biorever.sible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series"

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526438A (ja) * 2011-06-28 2014-10-06 フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド 抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
CN102875479B (zh) * 2012-10-24 2015-06-10 南京化工职业技术学院 喹唑啉二酮衍生物及其制备方法、其药物组合物及用途
CN102875479A (zh) * 2012-10-24 2013-01-16 南京化工职业技术学院 喹唑啉二酮衍生物及其制备方法、其药物组合物及用途
WO2017191130A2 (fr) 2016-05-04 2017-11-09 Oncoarendi Therapeutics Sa Inhibiteurs d'arginase et leurs applications thérapeutiques
CN105859695A (zh) * 2016-05-20 2016-08-17 苏州大学 2-芳基-3-(4-羟基-2h-吡喃-2-酮-3-基)吲哚衍生物及其合成方法
CN106008476A (zh) * 2016-05-27 2016-10-12 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基香豆素衍生物及其合成方法
CN106008476B (zh) * 2016-05-27 2019-02-26 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基香豆素衍生物及其合成方法
CN106008477A (zh) * 2016-06-02 2016-10-12 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法
CN106008477B (zh) * 2016-06-02 2019-02-26 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法
WO2021154997A1 (fr) * 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leurs méthodes d'utilisation
US11801234B2 (en) 2020-03-06 2023-10-31 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
US11866446B2 (en) 2020-08-26 2024-01-09 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2024012554A1 (fr) * 2022-07-14 2024-01-18 上海日馨医药科技股份有限公司 Agoniste de tpk et procédé de traitement de maladies neurodégénératives l'utilisant
CN115417877A (zh) * 2022-09-20 2022-12-02 杭州师范大学 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用
CN115417877B (zh) * 2022-09-20 2024-05-14 杭州师范大学 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用

Similar Documents

Publication Publication Date Title
WO2012025155A1 (fr) Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases
CA2714181C (fr) Modulateurs de l'ampk
US8629147B2 (en) Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
AU2017361078B2 (en) Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
AU2015296210B2 (en) Indolizine derivatives which are applicable to neurodegenerative diseases
WO2013129674A1 (fr) Nouveau dérivé de benzimidazole et son utilisation
AU2010359835A1 (en) Hydroxamate-based inhibitors of deacetylases
KR20200101330A (ko) Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물, 이의 염, 및 이들의 합성 방법
US20220242861A1 (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
EP3200589A1 (fr) Nouveaux modulateurs de l'activité du récepteur de 5-hydroxytryptamine 7 et leur procédé d'utilisation
CN107286166B (zh) 取代1，3，4，5-四氢-6h-吡咯并[4，3，2-ef][2]苯并氮杂-6-酮衍生物
JP2017520538A (ja) 新規キノリン誘導体及び神経変性疾患におけるそれらの使用
US20160355475A1 (en) Novel indole derivative compound and pharmaceutical composition comprising the same
US20110053925A1 (en) Hydroxamate-Based Inhibitors of Deacetylases
EP4058458A2 (fr) Nouvelles lactones fonctionnalisées constituant des modulateurs du récepteur de la 5-hydroxytryptamine 7 et leur procédé d'utilisation
CN110054622B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
US8648067B2 (en) Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands
US10071968B2 (en) Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain
US20110060009A1 (en) Hydroxamate-Based Inhibitors of Deacetylases
WO2009079630A1 (fr) 4-imidazolidinones comme inhibiteurs du canal potassique kv1.5
US11225480B2 (en) Malic enzyme inhibitors
WO2019182944A1 (fr) Nouveaux inhibiteurs de kinase présentant une activité anticancéreuse et leur procédé d'utilisation
CA2925294A1 (fr) Nouveaux analogues de 5-(phenoxymethyl)-1,3-dioxane fonctionnalises presentant une action inhibitrice du cytochrome p450
US20230265078A1 (en) Substituted pyrrolidine amines and amides vi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747625

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10747625

Country of ref document: EP

Kind code of ref document: A1